share_log

BRIEF-Protagonist Announces Plans To Initiate A Global Phase 3 Study For Rusfertide In Polycythemia Vera

路透社 ·  Mar 23, 2021 05:19
March 22 (Reuters) - Protagonist Therapeutics Inc :
   * PROTAGONIST ANNOUNCES PLANS TO INITIATE A GLOBAL PHASE 3 STUDY FOR RUSFERTIDE IN POLYCYTHEMIA VERA FOLLOWING INTERACTIONS WITH THE U.S. FOOD & DRUG ADMINISTRATION AND THE EUROPEAN MEDICINES AGENCY
   * PROTAGONIST - END-OF-PHASE-2 MEETING WITH FDA, & WRITTEN COMMENTS FROM EMA, SUPPORT ADVANCEMENT OF CLINICAL DEVELOPMENT PLAN FOR RUSFERTIDE IN PV

Source text for Eikon:  Further company coverage:

((Reuters.Briefs@thomsonreuters.com;)
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment